Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery shortlisted for BioNow Company of the Year Award

Sygnature Discovery is pleased to announce that we are a finalist for Company of the Year at the BioNow Annual Awards.

The prestigious BioNow Annual Awards showcase the best of the world class life sciences sector, recognise the outstanding success and achievements of those who have worked tirelessly this year, and spotlight the incredible progress that has been made during this challenging period.

The virtual ceremony will take place on Thursday 4th February 2021 and will bring the sector together, celebrate excellence and provide an opportunity to dress up!

In the last year, Sygnature has been able to continue our journey of growth and success. By adapting and supporting our scientists, Sygnature has been able to remain fully operational in a safe and sustainable manner throughout 2020 and into 2021. The acquisition of Alderley Oncology and XenoGesis have also been important steps in expanding our capabilities and fulfilling our mission of creating a truly integrated drug discovery service.

Sygnature was also recently named as the winner of the Outstanding Achievement Award at the Medilink UK Healthcare Virtual Business Awards 2020.

For more information on the Bionow Awards, read here.

Latest News

View All

Sygnature gains ISO:27001 certification for information security

Sygnature appoints Dr David Lustig to spearhead…

Sygnature Discovery expands US presence with Bay…

Freak chemistry accident turns Sygnature’s Senior VP…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.